Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
AVTX · Why this verdict
Why Avalo Therapeutics (AVTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Earnings have been mixed over the last 4 quarters (2 beats, 2 misses, average surprise of 2.25%), and options pricing shows elevated implied volatility of 124%, both consistent with the binary risk noted for this biotechnology name. Options | Implied volatility declines from the current 124% level and the earnings surprise trend turns more consistently positive. | →Stable |
| CounterHigh implied volatility partly reflects the large asymmetric upside already priced into the 109% take-profit target, meaning it may not signal pure downside risk. | ||
The risk/reward setup shows a 7.26 asymmetry ratio, with 109% upside to the take-profit target against just 7.0% downside to the stop-loss, and momentum has cleared the engine's 4.5 threshold at 5.3. Reward-to-risk math | The stock closes a meaningful portion of the gap toward its $39.37 take-profit target over the next 12 months. | →Stable |
| CounterMomentum is flagged as a soft warning (5.3 below the 5.5 preferred level) and the stock is already overbought at an RSI of 72 with volume in distribution, which could precede a pullback before the upside materializes. | ||
Insiders have sold $5,601,382 (0.566% of market cap) over the past 90 days across 24 sell transactions with zero buys, a level of insider selling the engine classifies as extreme and which failed the insider gate outright. Engine gate (failed) | Insider selling moderates back toward net-neutral, or the extreme-severity flag clears, over the next 12 months. | →Stable |
| CounterThe company sits in the biotechnology industry, which the engine flags as carrying binary outcome risk, and momentum and risk/reward are both currently favorable, which could mean the market has already priced in continued execution despite the insider selling. | ||
The business is cash-burning, with free cash flow at roughly -39,402% of revenue, no competitive moat, and broader quality concerns flagged by the engine. Quality breakdown | Free cash flow burn narrows meaningfully from its current deeply negative level over the next 12 months. | →Stable |
| CounterThe stock still screens as attractively valued and momentum has cleared its threshold, suggesting the market may be looking past current cash burn toward a future catalyst. | ||
The stock is overbought with an RSI of 72 and on-balance volume shows distribution even as price holds above the 200-day moving average, a mixed signal underneath the moderate momentum score. Momentum breakdown | RSI cools from overbought levels while price holds above the 200-day moving average, and volume shifts back to accumulation. | →Stable |
| CounterPrice remaining above the 200-day moving average is itself a bullish structural signal, and the momentum gate is only a soft warning (5.3 versus 5.5), not an outright failure. | ||
Earnings have been mixed over the last 4 quarters (2 beats, 2 misses, average surprise of 2.25%), and options pricing shows elevated implied volatility of 124%, both consistent with the binary risk noted for this biotechnology name.
→StableOptions
- Expectation
- Implied volatility declines from the current 124% level and the earnings surprise trend turns more consistently positive.
CounterHigh implied volatility partly reflects the large asymmetric upside already priced into the 109% take-profit target, meaning it may not signal pure downside risk.
The risk/reward setup shows a 7.26 asymmetry ratio, with 109% upside to the take-profit target against just 7.0% downside to the stop-loss, and momentum has cleared the engine's 4.5 threshold at 5.3.
→StableReward-to-risk math
- Expectation
- The stock closes a meaningful portion of the gap toward its $39.37 take-profit target over the next 12 months.
CounterMomentum is flagged as a soft warning (5.3 below the 5.5 preferred level) and the stock is already overbought at an RSI of 72 with volume in distribution, which could precede a pullback before the upside materializes.
Insiders have sold $5,601,382 (0.566% of market cap) over the past 90 days across 24 sell transactions with zero buys, a level of insider selling the engine classifies as extreme and which failed the insider gate outright.
→StableEngine gate (failed)
- Expectation
- Insider selling moderates back toward net-neutral, or the extreme-severity flag clears, over the next 12 months.
CounterThe company sits in the biotechnology industry, which the engine flags as carrying binary outcome risk, and momentum and risk/reward are both currently favorable, which could mean the market has already priced in continued execution despite the insider selling.
The business is cash-burning, with free cash flow at roughly -39,402% of revenue, no competitive moat, and broader quality concerns flagged by the engine.
→StableQuality breakdown
- Expectation
- Free cash flow burn narrows meaningfully from its current deeply negative level over the next 12 months.
CounterThe stock still screens as attractively valued and momentum has cleared its threshold, suggesting the market may be looking past current cash burn toward a future catalyst.
The stock is overbought with an RSI of 72 and on-balance volume shows distribution even as price holds above the 200-day moving average, a mixed signal underneath the moderate momentum score.
→StableMomentum breakdown
- Expectation
- RSI cools from overbought levels while price holds above the 200-day moving average, and volume shifts back to accumulation.
CounterPrice remaining above the 200-day moving average is itself a bullish structural signal, and the momentum gate is only a soft warning (5.3 versus 5.5), not an outright failure.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Avalo Therapeutics offers an unusually favorable 7.26 risk/reward setup with 109% upside to its take-profit target, but extreme insider selling that failed the engine's insider gate, ongoing cash burn, and overbought near-term momentum argue for caution despite the attractive setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.3 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -39402% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.7 |
- ▸Overbought (RSI 70)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 5.0 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.70 (n=1)
- ▸Analyst upside: 136%
Insider
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider selling — $5,529,874 (0.527% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.4 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.3 |
| support resistance | 1.8 |
| 52w position | 5.8 |
| gap | 6.0 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.9 |
| days to cover | 5.3 |
| volatility | 0.0 |
| put call | 6.7 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 8.3 |
| debt equity | 10.0 |
- ▸High IV: 87%
- ▸Above max pain $2
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 3.6 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:6.8>=5.5
- ASYMMETRY:7.0>=1.5
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- INSIDER:0.53%=EXTREME
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
7.00
Upside
+104.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.0B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor. Failed gate signal: INSIDER:0.53%=EXTREME.
The strongest dimensions are Value at 9.0, Sentiment at 7.6, and Momentum at 6.8; the weakest are Quality at 1.8, Technical at 4.0, and Catalyst at 4.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 7.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Asymmetric Risk Reward Setup
Trip ifThe reward-to-risk ratio falls below 3.0 from the current 7.26.
- P2Extreme Insider Selling
Trip ifInsider selling as a percentage of market cap falls below 0.2%, down from the current 0.566% extreme level.
- P3Cash Burning No Moat
Trip ifThe quality score rises above 4.0, clearing the engine's floor from the current 1.7.
- P4Overbought Distribution Momentum
Trip ifRSI falls below 70 from the current overbought level of 72.
- P5Mixed Earnings Elevated Volatility
Trip ifImplied volatility falls below 80% from the current 124% level.